# Modulation of the Expression of Papillomavirus (HPV) Oncoproteins to Major the Radiosensitivity: Trial Combining an Antiviral Agent VISTIDE and Radiochemotherapy in Cervical Cancers

> **NCT02515877** · PHASE1 · COMPLETED · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 15 (actual)

## Conditions studied

- Cervical Cancer

## Interventions

- **RADIATION:** External radiotherapy + curietherapy
- **DRUG:** Vistide
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT02515877
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2016-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02515877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02515877, "Modulation of the Expression of Papillomavirus (HPV) Oncoproteins to Major the Radiosensitivity: Trial Combining an Antiviral Agent VISTIDE and Radiochemotherapy in Cervical Cancers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02515877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*